Notably, in hematologic malignancies TIM-3 (or its specific ligand Galectin-9) blockade restores immune response in AML, follicular lymphoma (FL), and lymphoma [124,126,129]. The gene discussed is HAVCR2; the disease is acute myeloid leukemia.